__________________________________________________________________________________________
Molecular
Partners
DARPin therapy ( RDT ) and Switch-DARPin platforms are currently in pre-clinical stage .
Radio-DARPins are designed to deliver radioactive payloads to a broad range of tumor targets while sparing healthy tissues . We have designed our candidates to minimize kidney retention , a historic challenge for the approach , while increasing tumor uptake through precise control of how long the RDT candidates stay in the body . Our first RDT program , MP0712 , is a DLL3-targeted and 212 Pb-labeled Radio-DARPin Therapy candidate for small cell lung cancer patients , with initiation of a first in human clinical trial foreseen in 2025 , in collaboration with our partner Orano Med . Our RDT portfolio includes additional programs , as well as a collaboration with Novartis .”
212
Pb
Radio-DARPin Therapy
“ In addition , several programs of our Radio-
RADIOACTIVITY- MEDIATED
DNA DAMGE
DARPin
MP0712 ( Radio-DARPin Therapy )
SOLID TUMOR CELLS
F I L L A N D F I N I S H S E R V I C E S S I N C E 2 0 0 4
O UR GM P SERVICES Compounding & Fill and Finish
Your reliable global partner for Bioassays and Stability Studies
Secondary packaging ( including serialization ) Lab analysis and stability study Storage and logistics
+ 41
32 420 76 40 info @ baccinex . com https :// baccinex . com
healthscience @ sgs . com sgs . com / healthscience manufacturing-today . com 39